Myasthenia gravis-associated ryanodine receptor antibodies inhibit binding of ryanodine to sarcoplasmic reticulum.
Skeie
G O
GO
Department of Neurology, University of Bergen, Norway.
Lunde
P K
PK
Sejersted
O M
OM
Mygland
A
A
Aarli
J A
JA
Gilhus
N E
NE
D001323:Autoantibodies / Q000097:blood* / Q000494:pharmacology; D001667:Binding, Competitive; D002121:Calcium Channel Blockers; D006801:Humans; D018482:Muscle, Skeletal / Q000378:metabolism; D009157:Myasthenia Gravis / Q000150:complications / Q000276:immunology*; D012433:Ryanodine / Q000378:metabolism*; D019837:Ryanodine Receptor Calcium Release Channel / Q000276:immunology* / Q000302:isolation & purification / Q000378:metabolism; D012519:Sarcoplasmic Reticulum / Q000378:metabolism; D013945:Thymoma / Q000150:complications / Q000276:immunology*; D013953:Thymus Neoplasms / Q000150:complications / Q000276:immunology*
D001323:Autoantibodies; D002121:Calcium Channel Blockers; D019837:Ryanodine Receptor Calcium Release Channel; D012433:Ryanodine